Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Epioxa is GKOS' next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal disease. The NDA submission includes data from two Phase 3 pivotal trials of Epioxa, which successfully achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles. Likely Trend of GKOS Stock Following the News Following the announcement, shares of the company moved 1.7% south to $148.36 on Monday. In the past year, GKOS's shares have gained 80.2% compared with the industry's growth of 4.5%. The S&P 500 has gained 26.6% in the same time frame. However, the submission of the NDA for Epioxa to the FDA could positively impact Glaukos' stock price by boosting investor confidence. If approved, Epioxa would offer a first-of-its-kind non-invasive treatment for keratoconus, which is likely to attract strong demand and market share. The positive Phase 3 trial results further strengthen the co
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ [Yahoo! Finance]Yahoo! Finance
- Glaukos Submits New Drug Application to U.S. FDA for Epioxa™Business Wire
- Ophthalmic Diagnostic Equipment Pipeline Report Featuring Over 205 Companies and Prospective Products by Stages of Development, Segments, Region and Countries, Regulatory Path [Yahoo! Finance]Yahoo! Finance
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Truist Financial Co. from $152.00 to $185.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Announces Participation in the J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
GKOS
Earnings
- 11/4/24 - Beat
GKOS
Sec Filings
- 12/23/24 - Form 4
- 12/23/24 - Form 4
- 12/20/24 - Form 144
- GKOS's page on the SEC website